Pasar al contenido principal

ENTENDER COMO REGULA C3G EL METABOLISMO HEPATICO Y TUMORAL, Y SU IMPACTO EN EL MICROENTORNO TUMORAL. MEDIADORES DEL EFECTO DEL C3G PLAQUETARIO EN CANCER DE HIGADO

PID2022-137717OB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

New and Old Key Players in Liver Cancer

  • Cuesta Martínez, Ángel
  • Palao, Nerea
  • Bragado Domingo, Paloma
  • Gutiérrez Uzquiza, Álvaro
  • Herrera González, Blanca María
  • Sánchez Muñoz, Aranzazu
  • Porras Gallo, María Almudena
Liver cancer represents a major health problem worldwide with growing incidence and high mortality, hepatocellular carcinoma (HCC) being the most frequent. Hepatocytes are likely the cellular origin of most HCCs through the accumulation of genetic alterations, although hepatic progenitor cells (HPCs) might also be candidates in specific cases, as discussed here. HCC usually develops in a context of chronic inflammation, fibrosis, and cirrhosis, although the role of fibrosis is controversial. The interplay between hepatocytes, immune cells and hepatic stellate cells is a key issue. This review summarizes critical aspects of the liver tumor microenvironment paying special attention to platelets as new key players, which exert both pro- and anti-tumor effects, determined by specific contexts and a tight regulation of platelet signaling. Additionally, the relevance of specific signaling pathways, mainly HGF/MET, EGFR and TGF-β is discussed. HGF and TGF-β are produced by different liver cells and platelets and regulate not only tumor cell fate but also HPCs, inflammation and fibrosis, these being key players in these processes. The role of C3G/RAPGEF1, required for the proper function of HGF/MET signaling in HCC and HPCs, is highlighted, due to its ability to promote HCC growth and, regulate HPC fate and platelet-mediated actions on liver cancer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function

  • Herranz, Óscar
  • Berrocal, Pablo
  • Sicilia-Navarro, Carmen
  • Fernández-Infante, Cristina
  • Hernández-Cano, Luis
  • Porras, Almudena
  • Guerrero Arroyo, María del Carmen
C3G, a Rap1 GEF, promotes megakaryopoiesis and platelet function. Using transgenic and knock-out mouse models targeting C3G in megakaryocytes, we investigated whether C3G also affects the niche function of megakaryocytes during bone marrow (BM) recovery after myeloablation induced by 5-fluorouracil (5-FU), or total body irradiation (TBI) followed by bone marrow transplantation. C3G promoted megakaryocyte maturation and platelet production during recovery, along with increased white and red blood cell counts and enhanced survival of female mice after repeated doses of 5-FU. Additionally, megakaryocytes favored adipocyte differentiation through a C3G-mediated mechanism, likely involving Fgf1. Changes in the number or behavior of BM megakaryocytes and adipocytes influenced the hematopoietic stem cell pool, with C3G promoting its bias towards the myeloid-megakaryocytic lineage in both 5-FU- and TBI-ablated models. Therefore, C3G could be a potential target in therapies aimed at enhancing hematopoiesis in patients undergoing chemotherapy and/or BM transplantation., This work was supported by grants PID 2019-104143RB-C21 and PID2022-137717OB-C22 (CG), PID 2019-104143RB-C22 and PID2022-137717OB-C21 (AP) funded by MCIN/AEI/10.13039/501100011033 and ERDF “A way of making Europe”, and by grant SA078P20 (CG) funded by the Council of Education of Junta de Castilla y León, Spain and ERDF “A way of making Europe”. ÓH and CS-N are recipients of FPU fellowships from the Spanish Ministry of Education. PB, CF-I and LH-C are recipients of fellowships from the Council of Education of Junta de Castilla y León, Spain, and The Social European Funding. ÓH was also recipient of an EMBO Scientific Exchange Grant. The authors’ institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-funded by Junta de Castilla y León and ERDF (CLC-2017–01) and by the Scientific Foundation of the Spanish Association Against Cancer (Programa Excelencia 2022 EPAEC222641CICS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Platelet C3G protects from liver fibrosis, while enhancing tumor growth through regulation of the immune response

  • Baquero, Cristina
  • Iniesta-González, Minerva
  • Palao, Nerea
  • Fernández-Infante, Cristina
  • Cueto-Remacha, Mateo
  • Mancebo, Jaime
  • Cámara-Fuentes, Samuel de la
  • Rodrigo-Faus, María
  • Valdecantos, M. P.
  • Valverde, Ángela M.
  • Sequera, Celia
  • Manzano, Sara
  • Cuesta, Ángel M.
  • Gutiérrez-Uzquiza, Álvaro
  • Bragado, Paloma
  • Guerrero, Carmen
  • Porras, Almudena
Primary liver cancer usually occurs in the context of chronic liver disease (CLD), in association with fibrosis. Platelets have emerged as important regulators of CLD and liver cancer, although their precise function and mechanism of action need to be clarified. C3G (RapGEF1) regulates platelet activation, adhesion, and secretion. Here we evaluate the role of platelet C3G in chemically induced fibrosis and liver cancer associated with fibrosis using genetically modified mouse models. We found that while overexpression of full-length C3G in platelets decreased liver fibrosis induced by chronic treatment with CCl4, overexpressed C3G lacking the catalytic domain did not, although in both cases platelet recruitment to the liver was similar. In addition, C3G deletion in platelets (PF4-C3GKO mouse model) increased CCl4-induced liver damage and hepatic fibrosis, reducing liver platelets and macrophages. Moreover, early liver immune response to CCl4 was altered in PF4-C3GKO mice, with a remarkable lower activation of macrophages and increased monocyte-derived macrophages compared to WT mice. On the other hand, in response to DEN+CCl4, PF4-C3G WT mice exhibited more and larger liver tumors than PF4-C3GKO mice, accompanied by the presence of more platelets, despite having less fibrosis in previous steps. Liver immune cell populations were also differentially regulated in PF4-C3GKO mice, highlighting the higher number of macrophages, likely with a pro-inflammatory phenotype, present in the liver in response to chronic DEN+CCl4 treatment. Proteins upregulated or downregulated in platelet-rich plasma from PF4-C3GKO compared to WT mice might regulate the immune response and tumor development. In this regard, enrichment analyses using proteomic data showed changes in several proteins involved in platelet activation and immune response pathways. Additionally, the higher secretion of CD40L by PF4-C3GKO platelets could contribute to their antitumor effect. Therefore, platelet C3G presents antifibrotic and protumor effects in the liver, likely mediated by changes in the immune response. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness and Science, Innovation and Universities (PID2022-137717OB-C21 to AP/AMC; PID2019-104143RB-C22 to AP; PID2022-137717OB-C22 to CG; PID2019-104143RB-C21 to CG; PID2019-104991RB-I00 and PID2022-136959OB-I00 to PB, PID2020-117650RA-I00 and CNS2023-144109 to AG-U, PID-2021-122766OB-100 to AVM and funded by MICIU/AEI/10.13039/501100011033). All funding was cosponsored by the European ‘ERDF A way of making Europe’. CB was supported by Grant PID2019-104143RB-C22. NP was a recipient of a Formacion de Profesorado Universitario fellowship from the Spanish Ministry of Education. MI is supported by a predoctoral contract from Comunidad de Madrid. MC is a recipient of a predoctoral contract from UCM., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

New and Old Key Players in Liver Cancer

  • Cuesta Martínez, Ángel
  • Palao, Nerea
  • Bragado Domingo, Paloma
  • Gutiérrez Uzquiza, Álvaro
  • Herrera González, Blanca María
  • Sánchez Muñoz, Aranzazu
  • Porras Gallo, María Almudena
Liver cancer represents a major health problem worldwide with growing incidence and high mortality, hepatocellular carcinoma (HCC) being the most frequent. Hepatocytes are likely the cellular origin of most HCCs through the accumulation of genetic alterations, although hepatic progenitor cells (HPCs) might also be candidates in specific cases, as discussed here. HCC usually develops in a context of chronic inflammation, fibrosis, and cirrhosis, although the role of fibrosis is controversial. The interplay between hepatocytes, immune cells and hepatic stellate cells is a key issue. This review summarizes critical aspects of the liver tumor microenvironment paying special attention to platelets as new key players, which exert both pro- and anti-tumor effects, determined by specific contexts and a tight regulation of platelet signaling. Additionally, the relevance of specific signaling pathways, mainly HGF/MET, EGFR and TGF-β is discussed. HGF and TGF-β are produced by different liver cells and platelets and regulate not only tumor cell fate but also HPCs, inflammation and fibrosis, these being key players in these processes. The role of C3G/RAPGEF1, required for the proper function of HGF/MET signaling in HCC and HPCs, is highlighted, due to its ability to promote HCC growth and, regulate HPC fate and platelet-mediated actions on liver cancer.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Neuropilin-2 upregulation by stromal TGFβ1 induces lung disseminated tumor cells dormancy escape and promotes metastasis outgrowth.

  • Recalde-Percaz, L
  • de la Guia-Lopez, I
  • Linzoain-Agos, P
  • Noguera-Castells, A
  • Rodrigo-Faus, M
  • Jauregui, P
  • Lopez-Plana, A
  • Fernández-Nogueira, P
  • Iniesta-González, M
  • Cueto-Remacha, M
  • Manzano, S
  • Alonso, R
  • Moragas, N
  • Baquero, C
  • Palao, N
  • Dalla, E
  • Avilés-Jurado, F X
  • Vilaseca, I
  • León-Vintró, X
  • Camacho, M
  • Fuster, G
  • Alcaraz, J
  • Aguirre-Ghiso, J
  • Gascón, P
  • Porras, A
  • Carbó, N
  • Gutiérrez Uzquiza, Álvaro
  • Bragado Domingo, Paloma
Metastasis is the main cause of death from solid tumors. Therefore, identifying the mechanisms that govern metastatic growth poses a major biomedical challenge. Tumor microenvironment signals regulate the fate and survival of disseminated tumor cells (DTCs) in secondary organs. However, very little is known about the role of nervous system mediators in this process. We have previously reported that neuropilin-2 (NRP2) expression in breast cancer correlates with poor prognosis. Here, we show that NRP2 positively regulates the proliferation, invasion, and survival of breast and head and neck cancer cells in vitro. NRP2 deletion in tumor cells inhibits tumor growth in vivo and decreases the number and size of lung metastases by promoting lung DTCs quiescence. NRP2 deletion upregulates dormancy and cell cycle regulators expression and promotes DTCs reprograming into quiescence. Moreover, lung fibroblasts and macrophages induce NRP2 upregulation in DTCs through the secretion of TGFβ1. NRP2 facilitates lung DTC interaction with the extracellular matrix and promotes lung DTCs activation and metastasis. Therefore, we conclude that the TGFβ1-NRP2 axis is a new key dormancy-awakening inducer that promotes DTCs proliferation and lung metastasis development.